Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BD announces leadership changes

This article was originally published in Clinica

Executive Summary

Becton Dickinson (Franklin Lakes, New Jersey) has promoted Vincent Forlenza to president, effective from January 2009; and David Elkins is named as executive vice-president and CFO, effective from December 1 2008. Former president Edward Ludwig will remain as CEO and chairman; former executive vice-president Gary Cohen, and former CFO John Considine will join the Office of the CEO – a special strategic group for the CEO. Mr Considine will continue to be responsible for: integrated supply chain; IT; environment; health and safety; project management and engineering services; and security. Mr Forlenza, who has been with the company since 1980, most recently as executive vice-president and the head of BD Diagnostics, will oversee the medical, diagnostics and biosciences divisions, international and quality operations. Mr Elkins will be responsible for executive management and oversight of the company’s global financial operations. He joins from AstraZeneca, where in 2006 he became vice-president and CFO for North America and global marketing.

You may also be interested in...



Asia Regulatory Forum Update

Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.

Saudi Arabia adopts interim device authorisation regulation

Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.

Canada takes action to increase more adverse event reporting

The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel